Literature DB >> 14711160

Examining visual field defects in the paediatric population exposed to vigabatrin.

E L Spencer1, G F A Harding.   

Abstract

The antiepileptic drug, vigabatrin, has been linked to a specific pattern of visual field loss. The majority of studies have not included the paediatric population due to difficulties assessing visual field function. This is a particular problem as vigabatrin is effective against infantile spasms. A field-specific visual evoked potential was developed which consisted of a central stimulus (0-5 degrees radius) and a peripheral stimulus (30-60 degrees radius). Both stimuli consist of black and white checks which increase in size with eccentricity. Responses are recorded from occipital electrodes O2 and O1 referred to frontal electrode Fz. Electroretinograms and perimetry was performed were possible as a comparison. Thirty-nine children with epilepsy treated with vigabatrin aged from 3 to 15 years were included in the study; 35/39 children complied with the field-specific VEP, 26/39 complied with the ERG and 11/39 performed perimetry. Of these results, 18 children had normal ERG responses and eight had abnormal response. Visual field testing revealed four children had abnormal and seven had abnormal visual field results. The Field-specific VEP identified three of four abnormal perimetry results and six of seven normal perimetry results, giving a sensitivity of 75% and a specificity of 85.7%. When comparing perimetry results with the ERG parameters only the 30-Hz flicker amplitude, with a cut-off amplitude below 70 microV, gave a useful sensitivity of 75% and a specificity of 71%. The field-specific VEP is a useful alternative method that is both well tolerated by young children and gives a reliable indication of likely peripheral visual field loss associated with vigabatrin. The defect appears to have a similar prevalence in children as it does in adults.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711160     DOI: 10.1023/b:doop.0000005337.39947.83

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  25 in total

1.  Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.

Authors:  N R Miller; M A Johnson; S R Paul; C A Girkin; J D Perry; M Endres; G L Krauss
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

2.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

3.  Characteristics of a unique visual field defect attributed to vigabatrin.

Authors:  J M Wild; C Martinez; G Reinshagen; G F Harding
Journal:  Epilepsia       Date:  1999-12       Impact factor: 5.864

4.  Outer retinal dysfunction in patients treated with vigabatrin.

Authors:  C F Arndt; P Derambure; S Defoort-Dhellemmes; J C Hache
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

5.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

6.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Authors:  H Daneshvar; L Racette; S G Coupland; P J Kertes; A Guberman; D Zackon
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

7.  Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children.

Authors:  G F A Harding; E L Spencer; J M Wild; M Conway; R L Bohn
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

8.  No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group.

Authors:  F Mauguière; P Chauvel; J Dewailly; N Dousse
Journal:  Epilepsia       Date:  1997-03       Impact factor: 5.864

9.  Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients.

Authors:  C Liegeois-Chauvel; P Marquis; D Gisselbrecht; R Pantieri; D Beaumont; P Chauvel
Journal:  Epilepsia       Date:  1989       Impact factor: 5.864

Review 10.  Vigabatrin in the management of generalized seizures in children.

Authors:  R E Appleton
Journal:  Seizure       Date:  1995-03       Impact factor: 3.184

View more
  8 in total

1.  Effect of different stimulus configurations on the visual evoked potential (VEP).

Authors:  Naveen K Yadav; Diana P Ludlam; Kenneth J Ciuffreda
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

2.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

Review 3.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

4.  A frequency-tagging electrophysiological method to identify central and peripheral visual field deficits.

Authors:  Noémie Hébert-Lalonde; Lionel Carmant; Dima Safi; Marie-Sylvie Roy; Maryse Lassonde; Dave Saint-Amour
Journal:  Doc Ophthalmol       Date:  2014-05-10       Impact factor: 2.379

5.  Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.

Authors:  Rachel Dragas; Carol Westall; Tom Wright
Journal:  Doc Ophthalmol       Date:  2014-07-10       Impact factor: 2.379

6.  Retinal defect in children with infantile spasms of varying etiologies: An observational study.

Authors:  Michelle T McFarlane; Tom Wright; Blathnaid McCoy; O Carter Snead; Carol A Westall
Journal:  Neurology       Date:  2019-12-02       Impact factor: 9.910

7.  Treatment of infantile spasms.

Authors:  Philip J Overby; Eric H Kossoff
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.972

8.  Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.

Authors:  Carol A Westall; Tom Wright; Filomeno Cortese; Ananthavalli Kumarappah; O Carter Snead; Joseph R Buncic
Journal:  Neurology       Date:  2014-11-07       Impact factor: 9.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.